Fezolinetant,a new approved drug for the treatment of vasomotor symptoms in menopausal women
Fezolinetant has been approved by the U.S.Food and Drug Administration(FDA)for the treatment of moderate/severe vasomotor symptoms(VMS)in menopausal women.The Fezolinetant tablet is for oral use and is a neurokinin 3 receptor(NK3R)antagonist that blocks neurokinin B binding on the KNDy neuron.Clinical studys indicate that Fezolinetant can reduce the frequency and severity of VMS and improve quality of life.The mechanism of action,pharmacodynamics,pharmacokinetics,clinical study and safety were introduced.
国家科技期刊平台
NSTL
万方数据
